Roth Capital Cuts Price Target on Cytori Therapeutics (CYTX) Following 3Q15
Tweet Send to a Friend
Roth Capital maintained a Buy rating on Cytori Therapeutics, Inc. (NASDAQ: CYTX), and cut the price target of $2.50 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
